The tariff classification of Anastrozole Tablets imported in dosage form, from India
Issued October 23, 2013 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3004.90.9115
Headings: 3004
Product description
The subject product, Anastrozole tablets in 1 mg, is a medicinal preparation containing Anastrozole, a non-steroidal aromatase inhibitor, as the active ingredient. It is indicated for the treatment of breast cancer after surgery and for metastases in post-menopausal women.
Full text
N246640 October 23, 2013 CLA-2-30:OT:RR:E:NC:N2:238 CATEGORY: Classification TARIFF NO.: 3004.90.9115 Mr. Richard Philpott BluePoint Laboratories Eastgate Business Park Eastgate Road, Building 1 Little Island, Cork Ireland RE: The tariff classification of Anastrozole Tablets imported in dosage form, from India Dear Mr. Philpott: In your letter dated September 25, 2013, you requested a tariff classification ruling. The subject product, Anastrozole tablets in 1 mg, is a medicinal preparation containing Anastrozole, a non-steroidal aromatase inhibitor, as the active ingredient. It is indicated for the treatment of breast cancer after surgery and for metastases in post-menopausal women. The applicable subheading for the Anastrozole tablets, imported in dosage form, will be 3004.90.9115, Harmonized Tariff Schedule of the United States (HTS), which provides for: "Medicaments ... consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale: Other: Other: Other: Antineoplastic or immunosuppressive medicaments." The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at (646) 733-3033. Sincerely, Gwenn Klein Kirschner Acting Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Temozolomide capsules and Metronidazole tablets in dosage form, from India
The tariff classification of Cisplatin Injection (CAS 15663-27-1) in dosage form, from India. Correction to Ruling Number N274634
The tariff classification of Gemcitabine Injection in dosage form, from India
The tariff classification of Decitabine Injection in dosage form, from India
The tariff classification of Capecitabine Tablets in dosage form, from India
The tariff classification of Stivarga™ tablets imported in dosage form from Germany
The tariff classification of Fluorouracil Injection, USP, 50 mg/mL, from India
The tariff classification of Etoposide Injection, in dosage form, from India
The tariff classification of Docetaxel Injection, in dosage form, from India
The tariff classification of Mycophenolate Motefil Injection, in dosage form, from India
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →